another chance for SOFIIt seems that SOFI's price has fell back to touch the Triangle and a key area on the Weekly Chartby mmbrown17753
Easy Money on $PYPLBroke all resistance to touch 52 week high today, There's no going back from here. Next target is $76 . Longby Jay_Mata_LaxmiUpdated 775
TSLA turning bearish? Tesla had a strong attempt at breaking out but it got severely rejected. Often when price fails a directional move it attempts and tests the opposite direction. I would favour Lower price action based off o f this volume rejection. If prices loses any more of the upsloping trendliness Tesla can be in for much Lower price. by Trading-Capital5
SPCE key levelSPCE is on a downward trend, (it failed the asymmetrical triangle) but is there a possible reversal on the horizon? BJ Level indicator and the long wick candle near it gives possibility that the downward trend may be broken in the future. Also, around last month this time it had some greenish activity. The SRSI numbers are low, but it does have a positive cross over. Have a nice day by mmbrown17753
Members Daily Analysis Sept 9Markets hold majority if gap up after some early selling. IWM weakest indice on the day. Apple conference new iPhone, AirPods, watch If Apple sells due Semis catch a bid? Googl MSFT beaten down! 14:18by Trading-Capital4
WINT possible Bottom inBJ Key Level and cm williams vix fix indicator both hypothesizing the bottom is in. And it is also resting on a major support level. Caution still in a down trendby mmbrown17750
$AMD - Trendline provided support so farNASDAQ:AMD bounced from the trendline. Targets from the August 14 post remain unchanged. We'll see where it is by the end of the week. As always, I share my opinions and trades. I'm not suggesting anyone follow my trades. You do you.Longby PaperBozz6
TSLA contraction (retest of 260$)This is a quick update attached to the TSLL chart. I expect this breakout to give another bull trap for TSLA investors/traders. A surprise 50 basis point rate reduction could cause markets to rage in general. Investors will again realize TSLA is overvalued as it approaches 300$ and the stock will go to sub 185$ next year. Longby Apollo_21mil2
EPNH to 98-100$ area then go longThis stock will break it's Bollinger to the downside most likely tmmrw or Wednesday you will need to wait for it to get to 98-100$ area then buy a call for 2-3 weeks out to see the rewards I'll be keeping my eyes on it and also be putting if I enter the trade Longby DarioRuff223
PagSeguro _ Digital _ Ltd _ Distribution Prices _ Quarter 3 _ 4 PagSeguro _ Digital _ Ltd _ Distribution Prices _ Quarter 3 _ 4 _ Under _ Trading _ Venue _ NYSE. Descending (Drop/Repeat Cycle) will complete at the level of $8.04 ________________________________ 1st Distribution : $10.07 $10.28 $10.38 $10.98 _______________________ Distribution price = $13.84Longby Skill-Knowledge-Conduct0
can ZS stay above $167 by Friday 09/13?FQ4 results were solid. Billings grew 27% YoY, above consensus, and FY25 outlook was largely in line. However, with guidance assuming steep 2H accel compounded by salesforce disruption and more competition, investors remain cautious. Stock likely settles around $170 range, or ~30X EV/FY26 FCF.Longby KhanhC.Hoang0
Nvidia Looking Vulnerable To Start A More Important CorrectionWill this important momentum breakdown mark the top for Nvidia (and possibly Nasdaq and Bitcoin)? The start of a simple correction OR a vicious bear market? Let me know what you think. #nvidia #nasdaq #bitcoin #recession #unemploymentby Badcharts8
My levels to manage risks to bottom fishing $COINCoinbase's competitors: 1. Robinhood (HOOD) 2. Cash App (SQ) 3. Venmo (PYPL) Barclays bank revised its stance on Coinbase on Friday, shifting its price target down to $169 from $206 but upgrading the company to “Equal Weight” from “Underweight.”.by KhanhC.Hoang0
$QCOM - At critical supportNASDAQ:QCOM I posted on August 27 that Qualcomm might be forming a head and shoulders pattern. Look at it now. The right shoulder looks complete. It is currently sitting on critical neckline support. Remember, a head and shoulders pattern only validates if the price breaks below the neckline with multiple trading sessions closing below it. So, the pattern's validity still remains to be seen. As always, I share my opinions and trades. I'm not suggesting anyone follow my trades. You do you.by PaperBozz2
Palantir Bullish Long-Term PlayPalantir shares rose to a yearly high near $33 in the evening trading session on Friday, September 6, after announcement Palantir joins the S&P 500 index. Palantir was one of the strongest contenders for inclusion in the broad market S&P500 index. This inclusion, as well as Dell (DELL), comes after tech companies Super Micro (SMCI) and Crowdstrike (CRWD) also joined the index earlier this year. Technical 1-month graph indicates on Reversed Head-and-Shoulders structure in development. Potentially it can bring Palantir stocks, up to $100 per share over the next several years. by PandorraUpdated 6
Oracle Liquidation - Short or Sell | Yellowstone Bubble Anyone?Awhile back I posted a chart, where I referred to this current market as the "Yellowstone Bubble". Lol at the time, I was simply teasing about how ever since roughly season 4 of the show Yellowstone , it seems like everyone thinks they are some kind of tough-guy money-making, all-powerful market wizard. Google: "Yellowstone Oracle". Anyway, there's not much else to say here. The internet is a commodity.Shortby ChiefMacro1
Nvidia Go Bye Bye | Short or Take Profits Whenever news commentators feel the need to interview a CEO, and hail the CEO as some kind of benevolent "hero of the people", that is a pretty good indicator that something is awry. The same applies for rampant social media hype. At the end of the day, the chart & the macro backdrop tell the real story. NASDAQ:NVDA will collapse from here. Don't bother trying to buy any time soon, you will only be hurting yourself; this thing, along with the broader market has some significant adjusting (downward) to work through. Shortby ChiefMacro4
Long BROS @39.47 (oversold)Just went long bc I missed it at the close yesterday. Oversold and will hold each lot until overbought and profitable, adding lots as long as it's oversold. Record over the last 12 months for indicator and exit strategy on BROS: 40-0 Avg gain = 5.8% Median gain = 4.2% Range = +0.1% to 18.2% Cumulative 12M gain on equal dollar amount trades: 232% A weird one to trade. 12 of the wins gained less than 1% and 11 were over 10%. Last 7 trades were all +10% or more. This one can have very long losing streaks, though. Held as many as 17 lots at once before closing bc of a long downtrend. It's a great reminder to use position sizes that keep you from running out of capital before the stock runs out of downward momentum. This one gives trading opportunities really often, too. 40 in 12 months is a LOT, though that's partly bc of two really long losing streaks. Will update any adds or closing of positions.Longby redwingcoachUpdated 440
APPLE: Buy lower if this level breaks. Next target = 260.Apple is neutral on its 1D technical outlook (RSI = 45.352, MACD = -0.130, ADX = 33.865) as it is consolidating around the 1D MA50. The trend is a bearish one, correcting under LH and until they break, it will remain bearish. Much like the Channel Down corrections of 2023 and 2024, failure to cross above the top of the bearish pattern, should extend the selling to the 1D MA100 again, even the 1D MA200 if it fails. The 1D RSI of the prior tw fractals indicates that two main LH should be formed before the price recovers. This shows that we should take our time with AAPL and if the 1.5 Fib level breaks, buy on the 1D MA100 and the 1D MA200 for the long term. TP = 260.00 (the 2.5 Fibonacci level). See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##by InvestingScope8
NVDA: Wave 4NVDA appears to have completed 3 waves down, so looking for a retrace to 118-123 over the next week for wave 4, then a final plunge to $80 for wave 5by FiboTrader14415
$SMMT Stock Surges on Positive Lung Cancer Drug Trial ResultsShares of Summit Therapeutics (NASDAQ: NASDAQ:SMMT ) surged dramatically, soaring to an all-time high after the biotech firm reported promising results from its Phase 3 trial of ivonescimab, an experimental lung cancer treatment. The news sent the stock up by as much as 75.2% during intraday trading before settling at a 57.5% gain, marking a 54.77% increase by the close. These gains are driven by a powerful combination of strong clinical data and bullish market sentiment, positioning Summit as a rising star in the biotech space. Clinical Breakthrough: A Game-Changer for Lung Cancer Patients The Phase 3 trial, known as Harmoni-2, was conducted in China in collaboration with Summit's partner, Akeso. Ivonescimab was tested against Pembrolizumab (Keytruda), a standard-of-care treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1-positive tumors. PD-L1 is a protein that helps cancer cells evade the immune system, making it a key target in immunotherapy. The results were striking: ivonescimab achieved a median progression-free survival (PFS) time of 11.14 months compared to 5.82 months for Keytruda, nearly doubling the time before the disease progressed or led to death. The drug reduced the risk of disease progression or death by 49% compared to other treatments, demonstrating a statistically significant improvement in the trial’s primary endpoint. This positive data marks a critical validation for Summit's approach, particularly as it outperformed Keytruda across all subgroups, including both low and high PD-L1 expressions and across squamous and non-squamous forms of the disease. This broad efficacy profile could make ivonescimab a highly versatile and sought-after option in the oncology space. haba CEO Robert Duggan on a 'Historic Moment Summit Therapeutics CEO Robert Duggan hailed the trial results as a "historic moment" for ivonescimab, calling it the beginning of a shift in the landscape of lung cancer treatment. Duggan stated, “We believe this is the beginning of a landscape shift for treatment options for patients living with cancer.” Summit plans to initiate a multi-regional study of ivonescimab in early 2025, further expanding its global reach. Ivonescimab’s success in both the Harmoni-2 trial and previous Harmoni-A trials positions it as a potential blockbuster in the making. Earlier trials showed ivonescimab’s efficacy when combined with chemotherapy, even in challenging cases where other monoclonal antibodies had failed. Technical Analysis: Caution Amidst the Euphoria On the technical front, NASDAQ:SMMT 's rapid ascent has pushed the stock into overbought territory, with a Relative Strength Index (RSI) of 81.44. Such a high RSI indicates that the stock is ripe for a potential pullback or consolidation as traders digest the news and early profit-takers emerge. The daily chart also shows a gap-up pattern, a phenomenon often filled in subsequent trading sessions as the market corrects its initial exuberance. While the upward momentum remains strong, traders and investors should be mindful of the possibility of a short-term correction, especially given the sharp run-up. This could offer a more attractive entry point for those looking to capitalize on Summit's long-term potential. The Road Ahead: Blockbuster Potential and Key Risks Summit’s ivonescimab could be on the path to becoming a key player in the cancer treatment market, potentially rivaling established therapies like Keytruda. The planned multi-regional trial in 2025 will be crucial in confirming ivonescimab’s efficacy and safety on a global scale. However, investors should also consider the inherent risks. Early-stage biotechs like Summit face significant hurdles, including regulatory scrutiny, competitive pressures, and the financial burden of advancing clinical trials. Any setbacks in the drug’s development, unexpected adverse events, or delays could impact the company’s stock performance. Conclusion: Summit Therapeutics ( NASDAQ:SMMT ) has captured the market’s attention with its impressive trial results for ivonescimab, setting the stage for what could be a transformative journey in lung cancer treatment. While technical indicators suggest caution in the short term, the long-term outlook for NASDAQ:SMMT remains compelling. With continued clinical success and a strategic approach to expansion, Summit is well-positioned to carve out a significant niche in the oncology market. Investors should keep a close watch on the company’s progress as it navigates the complexities of bringing a potentially groundbreaking cancer therapy to market. As Summit continues to build on this momentum, the stock could offer substantial upside for those willing to weather the inherent volatility of the biotech sector.Longby DEXWireNews3
Oracle (ORCL): Bullish Outlook Ahead of EarningsToday, we’re getting the earnings report on ORCL, and we’ve had to adjust our last analysis accordingly. We are now looking at a more bullish scenario after our previous bearish outlook was invalidated. If Oracle holds the desired level, we believe our current wave count is accurate. The count is pretty straightforward, and we think we’re now in the intra wave (ii) of the larger wave 3. This wave (ii) might touch the trend channel again, though it doesn’t necessarily have to. The channel seems accurate as waves ((i)), ((ii)), and ((iii)) are all tagging it. It would have been ideal if wave ((iv)) had touched it as well, but perfection is rare in markets. We’re focusing on the area between $133.43 and $129 to hold. We’re not setting any limit orders for ourselves just yet, as we want to see if our new count proves correct before making any moves.Longby freeguy_by_wmc2
NVDIA Is disaster just ahead of us?NVIDIA corporation (NVDA) is on a 3-month pull-back, the first it had on a 1M basis since September - October 2023. The latter was simply a mid-Bull consolidation phase within the wider picture of a Channel Up pattern that started almost 10 years ago. The price is pulling-back from the Channel's top (Higher Highs trend-line) and if the 1M MACD forms a Bearish Cross, we should be preparing for a cyclical correction within the pattern which in the previous two times (November 2021 and October 2018 tops) it corrected back to the 1M MA50 (blue trend-line) to form a bottom. The Nov 2021 top was formed exactly at the time of the 1M MACD Bearish Cross, while the October 2018 top was formed 10 months after. If this is a 3-year Cycle then in October or November (2024) we should really see the extent of the correction. If not then this might be another Mid-bull consolidation and we may have (roughly) another 10-12 months before this Cycle tops. What do you think it's going to be?? ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇by TradingShot33